Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study assessing impact of a clinical decision support order set driving appropriate use of fidaxomicin on utilization of CDI drug treatments and associated clinical outcomes

Next Previous
Trial Profile

A retrospective study assessing impact of a clinical decision support order set driving appropriate use of fidaxomicin on utilization of CDI drug treatments and associated clinical outcomes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidaxomicin (Primary) ; Metronidazole; Vancomycin
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use

Most Recent Events

  • 19 Jul 2022 Results published in the Infectious Diseases and Therapy
  • 07 Feb 2022 New trial record
  • 03 Oct 2021 Primary endpoint (CDI recurrence within 30 days of completing therapy in patients who achieved clinical cure) has been met according to the Results presented at the IDWeek 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top